Photo of Ahmed Zakari, MD

Ahmed Zakari, MD

Medical Director of Digestive Tract Cancer, Medical Oncologist.

Research Area:

Expertise of Ahmed Zakari, MD

6 items. To interact with these items, press Control-Option-Shift-Right Arrow
Biography

Ahmed Zakari, MD, is board-certified in internal medicine, hematology and oncology physician. He was named Chief Fellow at Georgetown University Medical Center, Washington, DC, and is a recipient of the Golden Apple “Best Teacher”Award at Georgetown Medical School. His thesis, “Traumatic Rupture of the Thoracic Aorta,” received honors from all members of the jury. Dr. Zakari is a member of the American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH) and National Arab American Medical Association (NAAMA). Dr. Zakari also serves as the Associate Professor of Internal Medicine at the UCF College of Medicine. He is fluent in Arabic, English and French.

Education

Georgetown University Medical Center, Washington D.C.

Residency

The Brookdale University Hospital, Brooklyn, NY

Fellowship

Georgetown University Medical Center, Washington, D.C.

Specialty

Medical Oncology

Board Certifications

American Board of Internal Medicine

Publications of Ahmed Zakari, MD
  • Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study.
    , JOURNAL OF CLINICAL ONCOLOGY

  • Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
    , LANCET GASTROENTEROLOGY & HEPATOLOGY

  • Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment
    , CYTOTHERAPY

    More sources loaded

  • A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
    , ONCOLOGIST

  • A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers
    , CANCER INVESTIGATION

  • Generation of Highly Cytotoxic Natural Killer Cells for Treatment of Acute Myelogenous Leukemia Using a Feeder-Free, Particle-Based Approach
    , BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Associated Clinical Trials for Ahmed Zakari, MD